Sun Pharmaceutical Industries Limited’s Board of Directors has declared and approved an interim dividend of ₹10.50 per equity share.
On February 5, 2025, Sun Pharma share price opened at ₹1,773.80, up from its previous close of ₹1,765.25. However, at 9:36 AM, the share price of Sun Pharmaceutical Industries was trading at ₹1,753.50, down by 0.67% on the NSE.
The company has declared an interim dividend of ₹10.50 (Rupees Ten and Paise Fifty) per equity share of ₹1 (Rupee One) each for the financial year 2024-25. As announced on January 16, 2025, the record date for determining eligibility for the interim dividend is February 6, 2025. The payment of the interim dividend will be made on or before February 20, 2025.
Gross sales for the period reached ₹3,92,257 million, reflecting a growth of 9.1%. India formulation sales stood at ₹1,27,100 million, recording an impressive 13.7% increase. Meanwhile, US formulation sales amounted to $1,457 million, up by 5.7%, showcasing steady growth in international markets.
EBITDA, including other operating revenues, surged by 15.7% to ₹115,556 million, achieving an EBITDA margin of 29.2%. Net profit for the first nine months of FY25 was ₹87,792 million. On a like-for-like basis, the adjusted net profit stood at ₹90,953 million, marking a 24.3% year-on-year growth.
Sun Pharma is a global leader in speciality generics, offering a wide range of products in Specialty, Generics, and Consumer Healthcare. It is India’s largest pharmaceutical company and ranks among the top generic manufacturers in the US and emerging global markets.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: Feb 5, 2025, 9:40 AM IST
Nikitha Devi
Nikitha is a content creator with 6+ years of experience in the financial domain. Specialising in personal finance, investments, and market insights, Nikitha simplifies complex financial topics, making them accessible to readers.
Know MoreWe're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
